Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chronicles in drug discovery.

V K Khurdayan1, J Bozzo, J R Prous

  • 1Prous Science, Barcelona, Spain. service@prous.com.

Drug News & Perspectives
|January 5, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical overview of Fanhdi/Alphanate (plasma-derived, VWF-containing FVIII concentrate) in immune tolerance induction in haemophilia A patients with inhibitors.

Haemophilia : the official journal of the World Federation of Hemophilia·2015
Same author

A deleterious effect of aspirin on the antithrombotic properties of endothelial cells is not observed with platelets previously exposed to aspirin: studies in a flow system.

Platelets·2010
Same author

Effects of aspirin and indomethacin separately in red blood cells and platelets. Modulation of the adhesive and cohesive functions of platelets under flow conditions.

Platelets·2010
Same author

The year's new drugs and biologics--2007.

Drug news & perspectives·2008
Same author

Stem cells: therapeutic present and future.

Timely topics in medicine. Cardiovascular diseases·2008
Same author

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology·2008
Same journal

New drug discovery and development in India.

Drug news & perspectives·2013
Same journal

Are we living in the end of the blockbuster drug era?

Drug news & perspectives·2010
Same journal

Molecule of the Month. TAK-875.

Drug news & perspectives·2010
Same journal

Epigenetic alterations of tumor marker microRNAs: towards new cancer therapies.

Drug news & perspectives·2010
Same journal

Electroporation: a promising method for the nonviral delivery of DNA vaccines in humans?

Drug news & perspectives·2010
Same journal

Trioxaquines: hybrid molecules for the treatment of malaria.

Drug news & perspectives·2010
See all related articles

New brief reports highlight advancements in treating Duchenne Muscular Dystrophy with cellular and molecular therapies. Additionally, progress is noted in immunotherapy for multiple myeloma and drug development for acute respiratory distress syndrome and pulmonary hypertension.

Area of Science:

  • Medical research
  • Pharmacology
  • Biotechnology

Background:

  • Duchenne Muscular Dystrophy (DMD) requires novel therapeutic strategies.
  • Multiple myeloma, acute respiratory distress syndrome (ARDS), and pulmonary hypertension (PH) present significant clinical challenges.

Purpose of the Study:

  • To summarize recent brief reports on emerging therapeutic strategies.
  • To provide an overview of current and investigational treatments for various diseases.

Main Methods:

  • Review of recent brief reports on Duchenne Muscular Dystrophy (DMD) treatments.
  • Summary of advancements in immunotherapy for multiple myeloma.
  • Overview of current and developing treatments for acute respiratory distress syndrome (ARDS).
  • Compilation of drugs targeting key signaling pathways in pulmonary hypertension (PH).

Related Experiment Videos

Main Results:

  • DMD strategies include cellular, molecular (gene therapy, antisense), and pharmacotherapeutic approaches.
  • Immunotherapy for multiple myeloma is expanding with new antibodies and immunoconjugates.
  • Eight potential drugs are in development for ARDS, alongside current supportive care.
  • PH treatments target endothelin, prostacyclin, nitric oxide, and platelet-derived growth factor pathways.

Conclusions:

  • Multiple therapeutic avenues are being explored for Duchenne Muscular Dystrophy.
  • Significant progress is being made in immunotherapy and drug development for critical conditions like multiple myeloma, ARDS, and PH.